HC Wainwright Issues Optimistic Outlook for SANA Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Analysts at HC Wainwright upped their Q3 2024 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.09) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.61) EPS.

A number of other research firms have also weighed in on SANA. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Citigroup increased their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.01 on Thursday. The company has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $5.84. Sana Biotechnology has a 12-month low of $2.85 and a 12-month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04).

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. grew its holdings in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after acquiring an additional 12,154 shares during the period. Algert Global LLC purchased a new stake in Sana Biotechnology in the second quarter worth $73,000. Cornercap Investment Counsel Inc. bought a new position in Sana Biotechnology in the third quarter worth $67,000. XTX Topco Ltd purchased a new position in Sana Biotechnology during the second quarter valued at $100,000. Finally, Dark Forest Capital Management LP lifted its position in Sana Biotechnology by 112.0% during the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after buying an additional 14,430 shares during the period. 88.23% of the stock is owned by institutional investors.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 31.10% of the stock is owned by company insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.